Storia in 2 fonti

Ipsen succeeds in migraine trials; Tarsus buys iRenix for $75M upfront

Ipsen's Dysport meets Phase 3 endpoints in migraine, Tarsus acquires iRenix for $75M+, Alchemab raises $34M, and more.

Raccontata da

endpoints.news

fiercepharma.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo1 mese fa

Ipsen succeeds in migraine trials; Tarsus buys iRenix for $75M upfront

Ipsen's Dysport meets Phase 3 endpoints in migraine, Tarsus acquires iRenix for $75M+, Alchemab raises $34M, and more.

originale

fiercepharma.com1 mese fa

Ipsen’s Botox rival Dysport charts new horizons with dual phase 3 wins in migraine

In a first for the neurotoxin market, Ipsen announced Thursday that its Dysport has hit the goals in two phase 3 trials for the prevention of both episodic and chronic migraines. | In a first for the neurotoxin market,…

Leggi questa versione → originale

Timeline cronologica

giovedì 9 luglio 2026·endpoints.news
Ipsen succeeds in migraine trials; Tarsus buys iRenix for $75M upfront
Ipsen's Dysport meets Phase 3 endpoints in migraine, Tarsus acquires iRenix for $75M+, Alchemab raises $34M, and more.
giovedì 9 luglio 2026·fiercepharma.com
Ipsen’s Botox rival Dysport charts new horizons with dual phase 3 wins in migraine
In a first for the neurotoxin market, Ipsen announced Thursday that its Dysport has hit the goals in two phase 3 trials for the prevention of both episodic and chronic migraines.…